专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050079560A1 Detection and treatment of cancers of the colon 有权
标题翻译：检测和治疗结肠癌
公开(公告)号：US20050079560A1
公开(公告)日：2005-04-14
申请号：US10844216
申请日：2004-05-12
申请人： Myeong Nam , Juan Madoz-Gurpide , Hong Wang , David Misek , Samir Hanash
发明人： Myeong Nam , Juan Madoz-Gurpide , Hong Wang , David Misek , Samir Hanash
IPC分类号： A61K35/12 , C07K5/00 , C07K16/00 , C12N20060101 , C12P19/34 , C12Q1/68 , G01N33/53 , G01N33/574
CPC分类号： G01N33/574 , G01N33/57419
摘要： The present invention relates to compositions and methods for cancer therapies and diagnostics, including but not limited to, cancer markers. In particular, the present invention provides tumor antigens associated with specific cancers and diagnostic assays for the detection of such antigens and associated autoantibodies as indicative of the presence of specific cancers. The present invention further provides cancer immunotherapy utilizing the tumor antigens of the present invention.
摘要翻译：本发明涉及用于癌症治疗和诊断的组合物和方法，包括但不限于癌症标志物。特别地，本发明提供了与特异性癌症相关的肿瘤抗原和用于检测这些抗原和相关的自身抗体的诊断测定法，以指示特定癌症的存在。本发明进一步提供利用本发明的肿瘤抗原的癌症免疫疗法。

2. 发明申请

US20060275845A1 ANNEXIN PROTEINS AND AUTOANTIBODIES AS SERUM MARKERS FOR CANCER 审中-公开
标题翻译：作为癌症血清标记的新蛋白和自动体
公开(公告)号：US20060275845A1
公开(公告)日：2006-12-07
申请号：US11425439
申请日：2006-06-21
申请人： Samir HANASH , David Misek , Robert Hinderer , David Beer , Franck Brichory
发明人： Samir HANASH , David Misek , Robert Hinderer , David Beer , Franck Brichory
IPC分类号： G01N33/574
CPC分类号： G01N33/57488 , A61K39/0011 , G01N33/57423 , G01N33/57484 , G01N2333/4718 , G01N2800/52
摘要： The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of express on of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.
摘要翻译：本发明涉及通过检测来自受试者的血清中特异性膜联蛋白抗原的血清自身抗体的存在而在受试者中诊断，预后或易感性的筛选方法。本发明还提供了通过检测受试者生物样品中膜联蛋白的增加的表达水平来检测受试者中癌症的诊断和预后的筛选方法。本发明的方法还可以用于鉴定患有癌症风险的受试者。本发明的方法涉及使用受试者衍生的生物样品来确定膜联蛋白的表达或膜联蛋白衍生的肽或抗原的表达的发生和水平，和/或特定膜联蛋白抗原的循环自身抗体的发生和水平。本发明还提供了用于实施上述筛选方法的试剂盒。这样的试剂盒可用于筛选受试者增加的膜联蛋白水平，或用于检测对膜联蛋白的自身抗体，作为癌症的诊断性，预测性或预后指标。

3. 发明申请

US20070037227A1 ANNEXIN PROTEINS AND AUTOANTIBODIES AS SERUM MARKERS FOR CANCER 失效
标题翻译：作为癌症血清标记的新生蛋白和自身抗体
公开(公告)号：US20070037227A1
公开(公告)日：2007-02-15
申请号：US11425528
申请日：2006-06-21
申请人： Samir Hanash , David Misek , Robert Hinderer , David Beer , Franck Brichory
发明人： Samir Hanash , David Misek , Robert Hinderer , David Beer , Franck Brichory
IPC分类号： G01N33/574
CPC分类号： G01N33/57488 , A61K39/0011 , G01N33/57423 , G01N33/57484 , G01N2333/4718 , G01N2800/52
摘要： The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.
摘要翻译：本发明涉及通过检测来自受试者的血清中特异性膜联蛋白抗原的血清自身抗体的存在而在受试者中诊断，预后或易感性的筛选方法。本发明还提供了通过检测受试者生物样品中膜联蛋白的增加的表达水平来检测受试者中癌症的诊断和预后的筛选方法。本发明的方法还可以用于鉴定患有癌症风险的受试者。本发明的方法涉及使用受试者衍生的生物样品来确定膜联蛋白的表达的发生和水平或膜联蛋白衍生的肽或抗原的表达，和/或对特定的膜联蛋白抗原的循环自身抗体的发生和水平。本发明还提供了用于实施上述筛选方法的试剂盒。这样的试剂盒可用于筛选受试者增加的膜联蛋白水平，或用于检测对膜联蛋白的自身抗体，作为癌症的诊断性，预测性或预后指标。

4. 发明授权

US06677128B1 Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum 失效
公开(公告)号：US06677128B1
公开(公告)日：2004-01-13
申请号：US09464840
申请日：1999-12-16
申请人： Samir M. Hanash , David Misek , Robert Hinderer , Latha Prasannan
发明人： Samir M. Hanash , David Misek , Robert Hinderer , Latha Prasannan
IPC分类号： G01N33574
CPC分类号： G01N33/574 , G01N33/564 , G01N33/57423
摘要： The present invention relates to a method for identification of cellular protein antigens to which patients with cancer, or patients at risk for cancer, may develop autoantibodies. The method of the invention involves the use of patient derived sera for the identification of the cellular protein antigens using two-dimensional gel electrophoresis followed by Western Blot analysis. The identification of such protein antigens provides novel markers that can be utilized for screening, for diagnostics and prognosis of disease. The invention also provides for the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens in sera from individuals that may harbor such antibodies. The invention further relates to the use of the identified antigens as immunogens for stimulation of an immune response in patients expressing such protein antigens. The invention is demonstrated by way of example in which elevated levels of circulating autoantibodies reactive against a tumor specific antigen were identified in sera derived from a lung cancer patient. In addition, elevated levels of circulating autoantibodies reactive against several specific &bgr;-tubulin isoforms were detected in the sera of neuroblastoma patients.

5. 发明授权

US07955602B2 Annexin proteins and autoantibodies as serum markers for cancer 有权
标题翻译：膜联蛋白和自身抗体作为癌症的血清标志物
公开(公告)号：US07955602B2
公开(公告)日：2011-06-07
申请号：US12813070
申请日：2010-06-10
申请人： Samir M. Hanash , David Misek , Robert Hinderer , David Beer , Frank Brichory
发明人： Samir M. Hanash , David Misek , Robert Hinderer , David Beer , Frank Brichory
IPC分类号： A61K49/00 , G01N33/574 , G01N33/48 , C12Q1/66
CPC分类号： G01N33/57488 , A61K39/0011 , G01N33/57423 , G01N33/57484 , G01N2333/4718 , G01N2800/52
摘要： The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.
摘要翻译：本发明涉及通过检测来自受试者的血清中特异性膜联蛋白抗原的血清自身抗体的存在而在受试者中诊断，预后或易感性的筛选方法。本发明还提供了通过检测受试者的生物样品中膜联蛋白的增加的表达水平来检测受试者中癌症的诊断和预后的筛选方法。本发明的方法还可以用于鉴定患有癌症风险的受试者。本发明的方法涉及使用受试者衍生的生物样品来确定膜联蛋白的表达的发生和水平或膜联蛋白衍生的肽或抗原的表达，和/或对特定的膜联蛋白抗原的循环自身抗体的发生和水平。本发明还提供了用于实施上述筛选方法的试剂盒。这样的试剂盒可用于筛选受试者增加的膜联蛋白水平，或用于检测对膜联蛋白的自身抗体，作为癌症的诊断性，预测性或预后指标。

6. 发明申请

US20100330587A1 Annexin Proteins and Autoantibodies As Serum Markers For Cancer 有权
标题翻译：膜联蛋白和自身抗体作为血清标志物用于癌症
公开(公告)号：US20100330587A1
公开(公告)日：2010-12-30
申请号：US12813070
申请日：2010-06-10
申请人： Samir M. Hanash , David Misek , Robert Hinderer , David Beer , Franck Brichory
发明人： Samir M. Hanash , David Misek , Robert Hinderer , David Beer , Franck Brichory
IPC分类号： G01N33/53
CPC分类号： G01N33/57488 , A61K39/0011 , G01N33/57423 , G01N33/57484 , G01N2333/4718 , G01N2800/52
摘要： The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.
摘要翻译：本发明涉及通过检测来自受试者的血清中特异性膜联蛋白抗原的血清自身抗体的存在而在受试者中诊断，预后或易感性的筛选方法。本发明还提供了通过检测受试者生物样品中膜联蛋白的增加的表达水平来检测受试者中癌症的诊断和预后的筛选方法。本发明的方法还可以用于鉴定患有癌症风险的受试者。本发明的方法涉及使用受试者衍生的生物样品来确定膜联蛋白的表达的发生和水平或膜联蛋白衍生的肽或抗原的表达，和/或对特定的膜联蛋白抗原的循环自身抗体的发生和水平。本发明还提供了用于实施上述筛选方法的试剂盒。这样的试剂盒可用于筛选受试者增加的膜联蛋白水平，或用于检测对膜联蛋白的自身抗体，作为癌症的诊断性，预测性或预后指标。

7. 发明授权

US07759081B2 Annexin proteins and autoantibodies as serum markers for cancer 失效
标题翻译：膜联蛋白和自身抗体作为癌症的血清标志物
公开(公告)号：US07759081B2
公开(公告)日：2010-07-20
申请号：US11425528
申请日：2006-06-21
申请人： Samir M. Hanash , David Misek , Robert Hinderer , David Beer , Franck Brichory
发明人： Samir M. Hanash , David Misek , Robert Hinderer , David Beer , Franck Brichory
IPC分类号： G01N33/574
CPC分类号： G01N33/57488 , A61K39/0011 , G01N33/57423 , G01N33/57484 , G01N2333/4718 , G01N2800/52
摘要： The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.
摘要翻译：本发明涉及通过检测来自受试者的血清中特异性膜联蛋白抗原的血清自身抗体的存在而在受试者中诊断，预后或易感性的筛选方法。本发明还提供了通过检测受试者生物样品中膜联蛋白的增加的表达水平来检测受试者中癌症的诊断和预后的筛选方法。本发明的方法还可以用于鉴定患有癌症风险的受试者。本发明的方法涉及使用受试者衍生的生物样品来确定膜联蛋白的表达的发生和水平或膜联蛋白衍生的肽或抗原的表达，和/或对特定的膜联蛋白抗原的循环自身抗体的发生和水平。本发明还提供了用于实施上述筛选方法的试剂盒。这样的试剂盒可用于筛选受试者增加的膜联蛋白水平，或用于检测对膜联蛋白的自身抗体，作为癌症的诊断性，预测性或预后指标。

8. 发明授权

US06645465B2 Annexin proteins and autoantibodies as serum markers for cancer 有权
标题翻译：膜联蛋白和自身抗体作为癌症的血清标志物
公开(公告)号：US06645465B2
公开(公告)日：2003-11-11
申请号：US09370337
申请日：1999-08-06
申请人： Samir M. Hanash , David Misek , Robert Hinderer , David Beer , Franck Brichory
发明人： Samir M. Hanash , David Misek , Robert Hinderer , David Beer , Franck Brichory
IPC分类号： A61K4900
CPC分类号： G01N33/57488 , A61K39/0011 , G01N33/57423 , G01N33/57484 , G01N2333/4718 , G01N2800/52
摘要： The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.
摘要翻译：本发明涉及通过检测来自受试者的血清中特异性膜联蛋白抗原的血清自身抗体的存在而在受试者中诊断，预后或易感性的筛选方法。本发明还提供了通过检测受试者生物样品中膜联蛋白的增加的表达水平来检测受试者中癌症的诊断和预后的筛选方法。本发明的方法还可以用于鉴定患有癌症风险的受试者。本发明的方法涉及使用受试者衍生的生物样品来确定膜联蛋白的表达的发生和水平或膜联蛋白衍生的肽或抗原的表达，和/或对特定的膜联蛋白抗原的循环自身抗体的发生和水平。本发明还提供了用于实施上述筛选方法的试剂盒。这样的试剂盒可用于筛选受试者增加的膜联蛋白水平，或用于检测对膜联蛋白的自身抗体，作为癌症的诊断性，预测性或预后指标。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式